Medifocus Inc., a capital pool company, has made an announcement about the qualifying transaction with Celsion (Canada) Limited and its shareholders. The agreement between the companies is reported to be dated November 10, 2006.
In connection with the qualifying transaction, Medifocus has entered into a Share Exchange Agreement, under the terms of which the closing of the transaction is conditional upon, among other things, the completion of a concurrent public offering of company common shares, in an amount mutually acceptable to Medifocus and Celsion Canada. Subject to the terms and conditions of the Share Exchange Agreement, Medifocus has agreed to buy, and the shareholders of Celsion Canada have agreed to sell all of the Celsion shares to Medifocus. The direct purchase of the Celsion shares will be made by the payment of $166,667 and issuance on the closing date of 10,000,000 Medifocus Shares at a deemed issue price of $0.50 per share.
Medifocus Inc. is incorporated under the laws of Ontario province in Canada, and is a reporting issuer in the provinces of Ontario, Alberta and British Columbia.
Celsion (Canada) Limited is the owner of a proprietary medical technology, the Adaptive Phased Array technology, which precisely focuses microwave radiation to heat and destroys tumours. It is a corporation existing under the laws of Ontario. Its major shareholders are Dr. Augustine Cheung (the chief executive officer and a director of Celsion Canada), and Wy-Mann International Limited, a corporation incorporated under the laws of British Virgin Islands. Dr. Cheung is the registered and beneficial holder of fifty (50) Celsion Shares and Wy-Mann International is the registered and beneficial holder of twenty-five (25) Celsion Shares.
Under the qualifying transaction, the vendors are Dr. Augustine Cheung of Silver Spring, Maryland, Wy-mann International Limited, a British Virgin Islands corporation, Silver Lake Investment Partners Ltd., a British Virgin Islands corporation, Pearl Success Ltd., a British Virgin Islands corporation, Charles Shelton of Sparks, Maryland, and Douglas Stagnaco, Maryland.
As a result of the Qualifying Transaction, Celsion Canada will become a wholly-owned subsidiary of Medifocus. Upon completion of the Qualifying Transaction, Medifocus will carry on the business of Celsion Canada under current Celsion Canada management.